Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 5, 2022 (5 years ago)

Cyanocobalamin Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug: Out of Specification results for Assay

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Cyanocobalamin Injection, USP, 1,000 mcg per mL, For IM or SC Use Only, 1 mL Vial, Rx Only, Manufactured in India, for Auromedics Pharma LLC, NDC 55150-364-01.

Affected NDC 55150-0364-01

Compare with the code on your package — it is the most precise check available.

Drug: Cyanocobalamin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cyanocobalamin
NDC 55150-0364
1000 ug/mL Injection, Solution
Intramuscular
AuroMedics Pharma LLC Rx
Recalling firm
Aurobindo Pharma USA Inc.
NDC code
55150-364-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0766-2022 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cyanocobalamin recalls

See all
Class II · Moderate risk

Cyanocobalamin injection USP

Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-0032-01 D-0793-2026
Class II · Moderate risk

Cyanocobalamin injection USP

Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-0031-01 D-0792-2026

Other recalls by Aurobindo Pharma USA Inc.

All 2022 recalls
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk

Nebivolol Tablets

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025